Trials / Completed
CompletedNCT01783925
Eylea Post Marketing Surveillance(PMS)
Eylea Post Marketing Surveillance
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,206 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The objective of this PMS is to gain information about safety and efficacy in real practice as a regulatory commitment required by MFDS
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Patients in daily life clinical practice treatment receiving EYLEA according to indication on the label. |
Timeline
- Start date
- 2014-04-29
- Primary completion
- 2018-12-31
- Completion
- 2018-12-31
- First posted
- 2013-02-05
- Last updated
- 2023-11-07
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01783925. Inclusion in this directory is not an endorsement.